Urine Biomarker for Kidney Transplant Rejection
Sponsor
Exosome Diagnostics, Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05072951
Collaborator
(none)
750
48
Study Details
Study Description
Brief Summary
An adaptive sample collection to support biomarker evaluation for kidney transplant rejection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
750 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
An Adaptive Sample Collection to Evaluate a Biomarker for Kidney Transplant Rejection
Anticipated Study Start Date
:
Oct 1, 2021
Anticipated Primary Completion Date
:
Oct 1, 2023
Anticipated Study Completion Date
:
Oct 1, 2025
Outcome Measures
Primary Outcome Measures
- Biospecimen collection [3 years after last enrollment]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
-
Ability to provide informed consent
-
Kidney Transplant
Exclusion Criteria:
- Pediatric patients, under 18 years of age
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Exosome Diagnostics, Inc.
Investigators
- Study Chair: Sonia Kumar, Exosome Diagnostics, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Exosome Diagnostics, Inc.
ClinicalTrials.gov Identifier:
NCT05072951
Other Study ID Numbers:
- ECT2021-002
First Posted:
Oct 11, 2021
Last Update Posted:
Oct 11, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No